SCHEMBL4204404

SCHEMBL4204404

Cc1cc(N(C)C(=O)O)on1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.50
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
POLB P06746 2/20 0.38
VHL P40337 1/20 0.36
KMT2A Q03164 6/20 0.34
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
GLA P06280 2/20 0.33
CHRNA4 P43681 1/20 0.33
MEN1 O00255 3/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PKM P14618 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17319627 0.74
SCHEMBL3526212 0.72 HCAR2 (0.44) HCAR2ALDH1A1KDM4EUSP2TSHR
SCHEMBL17358166 0.71 SIRT3 (0.45) TP53
SCHEMBL5604308 0.70 BRAF (0.34) ALDH1A1KDM4ETSHRSMN1; SMN2KMT2A
SCHEMBL222184 0.67
SCHEMBL28594084 0.66 GAA (0.35) ALDH1A1KDM4EPOLBKMT2ARAB9A
SCHEMBL10677143 0.65 SMN1; SMN2 (0.44) ALDH1A1KDM4EUSP2TSHRSMN1; SMN2
SCHEMBL21816685 0.65 MAPT (0.40) ALDH1A1KDM4ESMN1; SMN2POLBKMT2A
Hydrochloric Acid SCHEMBL11453326 0.65 HCAR2 (0.96) HCAR2ALDH1A1KDM4EUSP2TSHR
SCHEMBL1896996 0.64 ALDH1A1 (0.66) HCAR2ALDH1A1SMN1; SMN2POLBVHL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088452-A1 Indole Orexin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-04-02 US disclosed
US-7504420-B2 Compounds which inhibit beta-secretase activity and methods of use COMENTIS, INC. (US) 2009-03-17 US disclosed
EP-1954276-A2 INDOLE OREXIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2008-08-13 EP disclosed
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-07-24 US disclosed
EP-1871739-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-01-02 EP disclosed
WO-2007061763-A2 INDOLE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 WO disclosed
WO-2006110668-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088452-A1 Indole Orexin Receptor Antagonists HCRTR2, HCRTR1, OXTR HCAR2 32/4885ALDH1A1 3088/4885KDM4E 1880/4885
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP HCAR2 3349/4885ALDH1A1 2912/4885KDM4E 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.